Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus for renal angiomyolipoma associated with tuberous sclerosis (case series)
ChiCTR2000039523Phase 4Recruiting
- Sponsor
- Department of Pharmacy, Peking University First Hospital
- Start
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of everolimus in kidney angiomyolipoma (AML), sponsored by Department of Pharmacy, Peking University First Hospital. Primary endpoint: Tumor size. Started Dec 2020; status: recruiting.
02
Drugs
everolimus
03
Conditions
kidney angiomyolipoma (AML)
Beyond the preview
Go deeper on ChiCTR2000039523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000039523.